Overcoming the Challenges of Decentralised Trials
4 years ago
By Josh Neil
Decentralised trials – clinical trials with virtual or online elements – have a huge number of advantages in the trial space. They are cheaper, faster, and allow for greater safety and recruitment of patients. But so far they have yet to see a positive uptake in big pharma companies, despite technology for virtual form-filling, wearable monitoring systems and online patient check-ins all existing and highly affordable for pharma companies.
To clarify the area for professionals who need to know, Proventa International created a White Paper on decentralised and virtual trials, looking at the innovations and trends shaping 2020, the technologies available to pharma companies, and the biggest challenges facing these new trials and how to overcome them. Below is just a sample of the full White Paper: to read the larger report, click here.
If you are unable to see the PDF below, please click here.
For more information on future events, including the upcoming Clinical Operations, CTSC and Pharmacovigilance meetings in November 2020, click here.
Joshua Neil, Editor
Proventa International
How to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
1 year agoHow to Reduce the Cost of Clinical Trial Supply Chain While Maintaining Quality and Efficiency
Clinical trial supply chain is a critical component of drug development, ensuring that drugs are available for testing, regulatory approval, and distribution. However, managing this supply chain can be challenging, with factors such as cost, quality, and efficiency all coming...
1 year ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
3 years ago
DeepMind’s AI Predicts Structures for More Than 350,000 Proteins
In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...
3 years agoDeepMind’s AI Predicts Structures for More Than 350,000 Proteins
In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...
3 years ago